Human immunoglobulin is being increasingly used in the treatment of autoimmune diseases. Despite being rare, thromboembolic complications like acute coronary syndrome (ACS) are possible and not reported in our country's literature. The authors present a case report of a 39 years old patient who developed an ACS after treatment of immune thrombocytopenic purpura with human immunoglobulin. A brief review of risk factors and mechanisms of this complication is performed.